Applied BioCode (6598.TW) Delnica Cena

Applied BioCode Cena

TWSE·ZAPRTO
31,10TWD-0,40 (-1,28 %)
Trg je zaprt

Revenue has compounded at 27,1% per year over the past 12 years to 475,20 Mio. TWD. Applied BioCode's net margin stands at −42,3%, up from −51,6% several years earlier. The stock trades about 62% above its 52-week low.

Cena delnice Applied BioCode

Obseg
Podrobnosti

Cena delnice

ⓘ

Kako prebrati ta grafikon

Ta grafikon sledi zgodovinski ceni delnice Applied BioCode skozi čas. Lahko preklapljate med dnevnimi, tedenskimi in mesečnimi prikazi ter izberete prilagojene časovne intervale – od enega dne do celotne razpoložljive zgodovine. Uporabite stikalo za prikaz sprememb cen v absolutnih valutnih pogojih ali kot odstotna sprememba glede na začetni datum.

Skupni prinos v primerjavi s cenovnim prinosom

Stikalo "Skupni prinos" vključuje reinvestirane dividende na vrh čistega gibanja cene. To je kritično, ker lahko dividende predstavljajo pomemben del dolgoročnih prinosov. Zgodovinsko so dividende predstavljale približno 40 % skupnega prihoda S&P 500. Vedno primerjajte skupni prinos pri vrednotenju prave zmogljivosti delnice glede na referenčni indeks.

Podatki o cenah v realnem času

Pri pregledu časovnega okvira enega dne grafikon prikazuje gibanja cen v realnem času intraday. To je koristno za opazovanje, kako se delnica Applied BioCode odziva na odpiranje trga, objave dobičkov ali novice v realnem času med trgovalno sejo.

Kaj iskati

Poglejte si dolgoročne trende (trajnostna gibanja navzgor ali navzdol v mesecih in letih), podporne in odporne ravni (cenovne cone, kjer se delnica ponavljajoče odbija ali spreminja smer) in volatilnost (kako se cena nihanja dan za dnem). Primerjava grafikona cene Applied BioCode z indeksom trga, kot je S&P 500, lahko razkrije, ali delnica presega ali zaostaja za širšim trgom.

Applied BioCode Zgodovina cene delnice
DatumApplied BioCode Cena
5. 8. 202631,10 TWD
4. 8. 202631,50 TWD
3. 8. 202631,00 TWD
31. 7. 202630,20 TWD
30. 7. 202628,75 TWD
29. 7. 202629,85 TWD
28. 7. 202629,10 TWD
27. 7. 202630,00 TWD
24. 7. 202627,70 TWD
23. 7. 202628,80 TWD
22. 7. 202627,85 TWD
21. 7. 202626,65 TWD
20. 7. 202626,85 TWD
17. 7. 202627,65 TWD
16. 7. 202625,20 TWD
15. 7. 202626,15 TWD
14. 7. 202623,80 TWD
13. 7. 202624,80 TWD
10. 7. 202622,85 TWD
9. 7. 202622,85 TWD
8. 7. 202622,75 TWD
7. 7. 202622,95 TWD
6. 7. 202623,25 TWD
3. 7. 202623,05 TWD
2. 7. 202622,75 TWD
1. 7. 202622,50 TWD
30. 6. 202622,85 TWD
29. 6. 202622,85 TWD
26. 6. 202622,80 TWD
25. 6. 202622,90 TWD
24. 6. 202623,20 TWD
23. 6. 202623,45 TWD
22. 6. 202623,75 TWD
18. 6. 202624,15 TWD
17. 6. 202624,40 TWD
16. 6. 202624,40 TWD
15. 6. 202625,00 TWD
12. 6. 202624,60 TWD
11. 6. 202624,50 TWD
10. 6. 202624,90 TWD
9. 6. 202625,00 TWD
8. 6. 202624,50 TWD
5. 6. 202624,50 TWD
4. 6. 202624,50 TWD
3. 6. 202624,10 TWD
2. 6. 202624,30 TWD
1. 6. 202624,20 TWD
29. 5. 202624,75 TWD
28. 5. 202624,75 TWD
27. 5. 202624,95 TWD
26. 5. 202624,85 TWD
25. 5. 202624,50 TWD
22. 5. 202624,30 TWD
21. 5. 202624,30 TWD
20. 5. 202624,20 TWD
19. 5. 202624,65 TWD
18. 5. 202624,50 TWD
15. 5. 202624,35 TWD
14. 5. 202623,75 TWD
13. 5. 202624,15 TWD
12. 5. 202623,35 TWD
11. 5. 202622,70 TWD
8. 5. 202622,50 TWD
7. 5. 202622,60 TWD
6. 5. 202622,90 TWD
5. 5. 202622,55 TWD
4. 5. 202622,55 TWD
30. 4. 202621,45 TWD
29. 4. 202621,95 TWD
28. 4. 202621,90 TWD
27. 4. 202621,90 TWD
24. 4. 202621,95 TWD
23. 4. 202621,85 TWD
22. 4. 202622,15 TWD
21. 4. 202622,25 TWD
20. 4. 202622,70 TWD
17. 4. 202622,80 TWD
16. 4. 202622,90 TWD
15. 4. 202622,80 TWD
14. 4. 202622,60 TWD
13. 4. 202622,60 TWD
10. 4. 202622,00 TWD
9. 4. 202621,80 TWD
8. 4. 202622,80 TWD
7. 4. 202622,55 TWD
2. 4. 202623,10 TWD
1. 4. 202623,40 TWD
31. 3. 202622,65 TWD
30. 3. 202623,30 TWD
27. 3. 202623,35 TWD
26. 3. 202623,55 TWD
25. 3. 202624,15 TWD
24. 3. 202623,65 TWD
23. 3. 202624,25 TWD
20. 3. 202624,95 TWD
19. 3. 202625,00 TWD
18. 3. 202624,80 TWD
17. 3. 202624,60 TWD
16. 3. 202624,80 TWD
13. 3. 202625,05 TWD
12. 3. 202624,55 TWD
11. 3. 202625,30 TWD
10. 3. 202623,90 TWD
9. 3. 202623,60 TWD
6. 3. 202624,65 TWD
5. 3. 202624,50 TWD
26. 2. 202625,30 TWD
25. 2. 202624,55 TWD
24. 2. 202624,35 TWD
23. 2. 202624,50 TWD
11. 2. 202624,05 TWD
10. 2. 202624,05 TWD
9. 2. 202625,65 TWD
6. 2. 202623,35 TWD
5. 2. 202624,30 TWD
4. 2. 202624,40 TWD
3. 2. 202624,10 TWD
2. 2. 202623,60 TWD
30. 1. 202624,10 TWD
29. 1. 202624,05 TWD
28. 1. 202624,80 TWD
27. 1. 202624,15 TWD
26. 1. 202623,95 TWD
23. 1. 202623,60 TWD
22. 1. 202624,05 TWD
21. 1. 202623,45 TWD
20. 1. 202623,90 TWD
19. 1. 202624,50 TWD
16. 1. 202624,45 TWD
15. 1. 202624,60 TWD
13. 1. 202623,40 TWD
12. 1. 202624,25 TWD
9. 1. 202623,15 TWD
8. 1. 202623,05 TWD
7. 1. 202622,30 TWD
6. 1. 202622,40 TWD
5. 1. 202622,35 TWD
2. 1. 202622,00 TWD
31. 12. 202522,00 TWD
30. 12. 202522,00 TWD
29. 12. 202522,30 TWD
26. 12. 202522,05 TWD
24. 12. 202521,60 TWD
23. 12. 202522,00 TWD
22. 12. 202522,10 TWD
19. 12. 202521,50 TWD
18. 12. 202521,25 TWD
17. 12. 202521,10 TWD
16. 12. 202521,10 TWD
15. 12. 202521,25 TWD
12. 12. 202521,10 TWD
11. 12. 202521,40 TWD
10. 12. 202521,45 TWD
9. 12. 202521,30 TWD
8. 12. 202521,40 TWD
5. 12. 202521,55 TWD
4. 12. 202521,40 TWD
3. 12. 202521,65 TWD
2. 12. 202521,65 TWD
1. 12. 202521,75 TWD
28. 11. 202522,10 TWD
27. 11. 202521,70 TWD
26. 11. 202521,55 TWD
25. 11. 202521,35 TWD
24. 11. 202521,20 TWD
21. 11. 202521,20 TWD
20. 11. 202520,95 TWD
19. 11. 202520,55 TWD
18. 11. 202521,00 TWD
17. 11. 202521,00 TWD
14. 11. 202521,10 TWD
13. 11. 202521,25 TWD
12. 11. 202521,30 TWD
11. 11. 202521,85 TWD
10. 11. 202522,70 TWD
7. 11. 202523,10 TWD
6. 11. 202522,70 TWD
5. 11. 202522,70 TWD
4. 11. 202522,65 TWD
3. 11. 202522,80 TWD
31. 10. 202522,90 TWD
30. 10. 202523,00 TWD
29. 10. 202522,55 TWD
28. 10. 202523,05 TWD
27. 10. 202523,00 TWD
23. 10. 202523,10 TWD
22. 10. 202523,15 TWD
21. 10. 202523,00 TWD
20. 10. 202523,10 TWD
17. 10. 202523,00 TWD
16. 10. 202522,95 TWD
15. 10. 202522,85 TWD
14. 10. 202522,75 TWD
13. 10. 202523,00 TWD
9. 10. 202523,10 TWD
8. 10. 202522,70 TWD
7. 10. 202522,95 TWD
3. 10. 202522,55 TWD
2. 10. 202522,60 TWD
1. 10. 202523,30 TWD
30. 9. 202523,65 TWD
26. 9. 202523,60 TWD
25. 9. 202523,00 TWD
24. 9. 202522,65 TWD
23. 9. 202522,60 TWD
22. 9. 202522,45 TWD
19. 9. 202522,70 TWD
18. 9. 202522,95 TWD
17. 9. 202523,05 TWD
16. 9. 202523,10 TWD
15. 9. 202523,05 TWD
12. 9. 202523,15 TWD
11. 9. 202523,35 TWD
10. 9. 202523,35 TWD
9. 9. 202523,25 TWD
8. 9. 202521,40 TWD
5. 9. 202520,85 TWD
4. 9. 202522,00 TWD
3. 9. 202520,60 TWD
2. 9. 202519,70 TWD
1. 9. 202519,35 TWD
29. 8. 202519,60 TWD
28. 8. 202519,55 TWD
27. 8. 202519,55 TWD
26. 8. 202519,55 TWD
25. 8. 202519,60 TWD
22. 8. 202519,35 TWD
21. 8. 202519,35 TWD
20. 8. 202519,25 TWD
19. 8. 202519,30 TWD
18. 8. 202519,55 TWD
15. 8. 202519,55 TWD
14. 8. 202519,55 TWD
13. 8. 202519,50 TWD
12. 8. 202519,50 TWD
11. 8. 202519,50 TWD
8. 8. 202519,90 TWD
7. 8. 202520,00 TWD
Access this data via the Eulerpool API
Get Free API Key

Applied BioCode Prihodek, EBIT, Neto dobiček

  • 3 leta

  • 5 let

  • 10 let

  • 25 let

  • Največ

Prihodek
EBIT
Neto dobiček
Details
Date
Prihodek
EBIT
Neto dobiček
1. jan. 2019
104,69 Mio. TWD
−273,46 Mio. TWD
−280,07 Mio. TWD
1. jan. 2020
299,02 Mio. TWD
−99,16 Mio. TWD
−103,50 Mio. TWD
1. jan. 2021
319,96 Mio. TWD
−162,31 Mio. TWD
−165,20 Mio. TWD
1. jan. 2022
390,30 Mio. TWD
−181,93 Mio. TWD
−184,73 Mio. TWD
1. jan. 2023
395,17 Mio. TWD
−186,70 Mio. TWD
−164,20 Mio. TWD
1. jan. 2024
343,07 Mio. TWD
−277,67 Mio. TWD
−260,81 Mio. TWD
1. jan. 2025
475,20 Mio. TWD
−223,33 Mio. TWD
−201,20 Mio. TWD
1. jan. 2026 (e)
0,00 TWD
0,00 TWD
0,00 TWD

Applied BioCode Izkaz poslovnega izida, Bilanca stanja, Izkaz denarnih tokov

Zadnja posodobitev 7. avg. 2026, 00:32
 
PRIHODKIMio. TWD
RAST PRIHODKOV%
BRUTTOMARJA%
BRUTO DOHODEKMio. TWD
EBITMio. TWD
EBIT MARJA%
ČISTI DOHODEKMio. TWD
RAST ČISTEGA DOBIČKA%
DELNICEMio.
20132014201520162017201820192020202120222023202420252026e
26,0015,0023,0011,0026,0037,00104,00299,00319,00390,00395,00343,00475,00–
–−42,3153,33−52,17136,3642,31181,08187,506,6922,261,28−13,1638,48–
7,6913,3326,0936,3630,7743,2450,0064,5559,2560,0067,8559,1854,74–
2,002,006,004,008,0016,0052,00193,00189,00234,00268,00203,00260,00260,00
−83,00−162,00−221,00−194,00−263,00−267,00−273,00−99,00−162,00−181,00−186,00−277,00−223,00–
−319,23−1080,00−960,87−1763,64−1011,54−721,62−262,50−33,11−50,78−46,41−47,09−80,76−46,95–
−208,00−71,00−21,00−135,00−263,00−268,00−280,00−103,00−165,00−184,00−164,00−260,00−201,00–
–−65,87−70,42542,8694,811,904,48−63,2160,1911,52−10,8758,54−22,69–
102,65102,65102,6540,0546,6659,4271,1681,5981,7381,6981,77102,79102,65102,65
Podrobnosti

Ključne številke izkaza poslovnega izida

ⓘ

Prihodki in rast prihodkov

Prihodki so izhodišče vsakega izkaza poslovnega izida — merijo skupne prodaje, ki jih Applied BioCode ustvari iz svoje osnovne dejavnosti. Rast prihodkov (izražena kot sprememba v odstotkih od leta do leta) je eden od najpomembnejših kazalnikov poslovnega zagona. Trajnostna rast nad 10 % letno se šteje za močno, medtem ko padajoči prihodki predstavljajo resno opozorilo, ki zahteva preiskavo.

Bruto marža

Bruto marža = (Prihodki − Stroški prodanih blaga) ÷ Prihodki. Razkriva, kolikšen odstotek vsakega dolarja prihodkov Applied BioCode zadrži po neposrednih proizvodnih stroških. Visoke bruto marže (nad 50 %) so značilne za poslovanja z majhno količino sredstev, kot so programska oprema in blagovne znamke, medtem ko kapitalno intenzivne industrije, kot je proizvodnja, pogosto delujejo z manj kot 30 %. Primerjajte bruto marzho Applied BioCode s konkurenti v industriji in jo spremljajte skozi čas, da ugotovite izboljšano ali poslabšano cenovno moč.

EBIT in marža EBIT

EBIT meri operativni dobiček — tisto, kar ostane po odbitku vseh operativnih stroškov (vključno s stroški R&R, prodaje in administracije) od bruto dobička. Marža EBIT to prikaže kot odstotek prihodkov. Ker izključuje obresti in davke, EBIT omogoča poštene primerjave med podjetji z različnimi ravnmi dolga in davčnimi pristojnosti. Naraščajoča marža EBIT kaže na izboljšano operativno učinkovitost.

Neto dohodek in dobiček na delnico (EPS)

Neto dohodek je končni dobiček podjetja po vseh stroških, obrestih in davkih. Deljenje neto dohodka s številom Outstanding delnic vam daje EPS — en sam najbolj vpliven metriko pri vrednotenju delnic. Dosledna rast EPS je glavni pogon dolgoročnega rasta cene delnice. Vedno preverite, ali rast EPS izvira iz resničnega izboljšanja dobička ali iz odkupa delnic, ki zmanjšuje število delnic.

Izdane delnice

Skupno število delnic, ki jih je Applied BioCode izdal. Padajoče število delnic (preko odkupa) dviguje EPS in signalizira zaupanje managementa. Naraščajoče število delnic (preko izdaje delnic) razvodnjuje obstoječe lastnike. Vedno spremljajte to število skupaj z EPS, da dobite celovito sliko ustvarjanja vrednosti na delnico.

Ocene analitikov

Projicirane številke predstavljajo soglasne ocene strokovnih analitikov. Primerjajte te napovedi z zgodovinskim stopnjami rasti Applied BioCode, da ocenite, ali so pričakovanja realistična. Podjetje, ki dosledno presega soglasne ocene, ima svoje delnice nagrajene skozi čas, medtem ko se ponovljeni zamiki bremenijo zaupanja vlagateljev.

Applied BioCode robni dobički delnice

Analiza Applied BioCode marge prikazuje bruto maržo, maržo EBIT ter dobičkovno maržo Applied BioCode. Marža EBIT (EBIT/prodaja) označuje, kolikšen odstotek prodaje ostane kot operativni dobiček. Dobičkovna marža kaže, kolikšen odstotek prodaje ostane za Applied BioCode.

  • 3 leta

  • 5 let

  • 10 let

  • 25 let

  • Največ

Bruto marža
Marža EBIT
Dobičkovna marža
Details
Date
Bruto marža
Marža EBIT
Dobičkovna marža
1. jan. 2019
50,59 %
−261,20 %
−267,52 %
1. jan. 2020
64,72 %
−33,16 %
−34,61 %
1. jan. 2021
59,18 %
−50,73 %
−51,63 %
1. jan. 2022
60,00 %
−46,61 %
−47,33 %
1. jan. 2023
68,01 %
−47,25 %
−41,55 %
1. jan. 2024
59,46 %
−80,94 %
−76,02 %
1. jan. 2025
54,90 %
−47,00 %
−42,34 %
1. jan. 2026 (e)
54,90 %
0,00 %
0,00 %

Applied BioCode Prihodek na delnico, EBIT, Dobiček na delnico

Applied BioCode dobiček na delnico torej kaže, koliko prihodka je Applied BioCode ustvaril na delnico v danem obdobju. Dobiček pred obrestmi in davki na delnico kaže, koliko operativnega dobička spada v vsako delnico. Dobiček na delnico kaže, koliko dobička spada v vsako delnico.

  • 3 leta

  • 5 let

  • 10 let

  • 25 let

  • Največ

Prihodek na delnico
EBIT na delnico
Dobiček na delnico
Details
Date
Prihodek na delnico
EBIT na delnico
Dobiček na delnico
1. jan. 2019
1,47 TWD
−3,84 TWD
−3,94 TWD
1. jan. 2020
3,66 TWD
−1,22 TWD
−1,27 TWD
1. jan. 2021
3,91 TWD
−1,99 TWD
−2,02 TWD
1. jan. 2022
4,78 TWD
−2,23 TWD
−2,26 TWD
1. jan. 2023
4,83 TWD
−2,28 TWD
−2,01 TWD
1. jan. 2024
3,34 TWD
−2,70 TWD
−2,54 TWD
1. jan. 2025
4,63 TWD
−2,18 TWD
−1,96 TWD
1. jan. 2026 (e)
0,00 TWD
0,00 TWD
0,00 TWD

Applied BioCode poslovni model in analiza delnice

Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice.

Applied BioCode vrednotenje po pošteni vrednosti

Podrobnosti

Ocena poštene vrednosti

ⓘ

Kaj je poštena vrednost?

Poštena vrednost je ocena prave "vrednosti" delnice na podlagi njenih finančnih temeljnih podatkov, neodvisno od trenutne tržne cene. Če je izračunana poštena vrednost višja od trenutne cene delnice, je delnica lahko podocenjena — in obratno. Ta grafikon prikazuje tri različne pristope poštene vrednosti, tako da jih lahko medsebojno primerjate.

Poštena vrednost na podlagi dobitka

Izračuna se z množenjem trenutnega dobitka na delnico (EPS) s povprečnim zgodovinskim razmerjem cena/dobiček v izbranem večletnem obdobju. Glajenje v več letih odpravlja začasne konice ali padce. Če ta poštena vrednost presega tržno ceno, to nakazuje, da je delnica poceni v primerjavi z njeno sposobnostjo ustvarjanja dobička.

Primer: Poštena vrednost (dobiček) 2022 = EPS 2022 × Povprečno razmerje KGV 2019–2021

Poštena vrednost na podlagi prihodka

Izpeljana z množenjem prihodka na delnico s povprečnim zgodovinskim razmerjem cena/prodaja. Ta metoda je posebej uporabna za podjetja s spremenljivim ali začasno zmanjšanim dobitkom, saj je prihodek ponavadi bolj stabilen kot dobiček. Odgovarja: "Po kakšni ceni je trg v preteklosti vrednoval vsak dolar prodaje tega podjetja?"

Primer: Poštena vrednost (prihodek) 2022 = Prihodek na delnico 2022 × Povprečno razmerje KUV 2019–2021

Poštena vrednost na podlagi dividende

Izračuna se z deljenjem dividende na delnico s povprečno zgodovinsko donosnostjo dividend. Ta pristop je najbolj relevantan za zrela, dosledno dividende izplačujoča podjetja. Če je dobljena poštena vrednost višja od trenutne cene, to pomeni, da delnica ponuja boljšo donosnost kot njeno zgodovinsko povprečje.

Primer: Poštena vrednost (dividenda) 2022 = Dividenda na delnico 2022 ÷ Povprečna donosnost 2019–2021

Kako uporabljati ta grafikon

Kadar se vse tri črte poštene vrednosti zbližajo nad trenutno ceno, je to okrepitev primera, da je delnica podocenjena. Kadar se razhajajo, preiskati, zakaj — morda gre za strukturni premik v robnih dobičkih, politiki izplačil ali stopnji rasti. Napredne ocene na desni razširijo analizo z uporabo napovedanih temeljnih podatkov, kar vam pomaga oceniti, ali trenutna cena že odraža pričakovanja prihodnje rasti.

Applied BioCode vrednotenje po zgodovinskem razmerju cena-dobiček, večkrtniku EBIT in razmerju cena-prihodki

Applied BioCode letna donosnost

Podrobnosti

Letna donosnost

ⓘ

Kaj prikazuje ta grafikon

Ta grafikon razdeli skupno letno donosnost v dve komponenti: donosnost cene (dobički ali izgube iz gibanja cene delnice) in donosnost dividende (dohodek prejeto od izplačil dividend). Skupaj predstavljajo skupno donosnost, ki bi jo je vlagatelj zaslužil v vsakem koledarskem letu.

Donosnost cene

Donosnost cene meri odstotnino spremembe cene delnice od 1. januarja do 31. decembra vsakega leta. Pozitivne črte nakazujejo, da se je delnica podražila; negativne črte kažejo padec. To je komponenta, na katero se večina vlagateljev osredotoča, vendar le delno pripoveduje zgodbo — posebej za delnice, ki izplačujejo dividende.

Donosnost dividende

Donosnost dividende predstavlja dohodek, ustvarjen z dividendami, izplačanimi v letu, izraženo kot odstotek začetne cene delnice. Čeprav se lahko zdi majhna v kateremkoli letu (navadno 1–4 % za uveljavljenih podjetij), se dividende sčasoma sestavljajo in so zgodovinsko prispevale približno 40 % skupne donosnosti borznega trga.

Kaj poiskati

Preglejte, koliko let je bilo pozitivnih nasproti negativnim donosnostim, da bi ocenili doslednost. Delnica, ki ima večino let s pozitivnimi rezultati in majhnimi upadi, nakazuje manjše tveganje. Primerjajte tudi letno donosnost s primerjalnim indeksom — dosledna preseganja trga je značilnost močne naložbe. Obratite pozornost na najslabša leta: razumevanje tveganja padca je enako pomembno kot lovljenje potenciala rasti.

Applied BioCode izdane delnice

Število delnic podjetja Applied BioCode je bilo 102,65 Mio. v letu 2025. To kaže, na koliko delnic je razdeljeno Applied BioCode. Ker so delničarji lastniki podjetja, vsaka delnica predstavlja majhen del lastništva podjetja.

  • 3 leta

  • 5 let

  • 10 let

  • 25 let

  • Največ

Število delnic
Details
Date
Število delnic
1. jan. 2019
71,16 Mio. Delnice
1. jan. 2020
81,59 Mio. Delnice
1. jan. 2021
81,73 Mio. Delnice
1. jan. 2022
81,69 Mio. Delnice
1. jan. 2023
81,77 Mio. Delnice
1. jan. 2024
102,79 Mio. Delnice
1. jan. 2025
102,65 Mio. Delnice
1. jan. 2026 (e)
102,65 Mio. Delnice
Za Applied BioCode trenutno ni razpoložljivih ciljev cen in napovedi.

Struktura lastnikov delnic Applied BioCode

% Ime
9,73018%
Hsu (Fu-Lung)
Hsu (Fu-Lung)
9,16736%
Maxwell Sensors Incorporation
Maxwell Sensors Incorporation
3,94085%
Eureka BioVenture Partners
Eureka BioVenture Partners
3,06682%
GVT Fund L.P.
GVT Fund L.P.
3,01164%
Celerus Diagnostics
Celerus Diagnostics
2,48303%
Cathay Venture Inc.
Cathay Venture Inc.

Applied BioCode Beneficial Ownership Filings (SEC 13D/G)

Free Float
69,4%
Float Shares
-
Shares Outstanding
-

Applied BioCode Uprava in upravni odbor

14 members · 0 % women

Management

ZH

Mr. Zohn-Zen Ho

Founder, Chief Technology Officer, General Manager, Director · od 2008

–
LH

Mr. Liang-Kai Huang

Chief Financial Officer, Corporate Governance Officer

–
MA

Mr. Michael Aye

Vice President-Molecular Products

–
DW

Mr. Donald Wong

Vice President-Productions

–
YC

Mr. Youning Chen

Deputy General Manager-Taiwan Sub-Subsidiary

–
GK

Gerald Kowalski

Deputy General Manager-Operation

–

Board of Directors

JL

Mr. Jia-Long Lee

Chairman of the Board · od 2016

–
BJ

Mr. Benjamin Jen

Director

–
LL

Lizzie Lee

Director

–
WT

Mr. Wen-Jing Tsai

Independent Director

–
JT

James Tsu

Independent Director

–
JW

Jim Wu

Independent Director

–

Pogosto postavljena vprašanja o delnici Applied BioCode

The business model of Applied BioCode Corp is centered around providing innovative molecular diagnostics solutions. They specialize in the development, manufacture, and commercialization of barcode technology-based multiplex testing systems for diagnostics laboratories. With their proprietary BioCode-1000 system, they offer a cost-effective and scalable solution for high-throughput testing of various diseases such as cancer, infectious diseases, and genetic disorders. Applied BioCode Corp aims to improve patient outcomes by delivering accurate and timely diagnostic results to healthcare professionals. Their advanced technology, coupled with a commitment to continuous innovation, positions them as a leading player in the field of molecular diagnostics.

Applied BioCode Corp is primarily active in the biotechnology industry.

The main competitors of Applied BioCode Corp in the market include companies such as Illumina, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, and QIAGEN.

Applied BioCode Corp is a leading biotechnology company specializing in developing and commercializing molecular diagnostic systems. Founded in [insert year], Applied BioCode Corp has a rich history in the field of biotech and has consistently delivered innovative solutions for healthcare professionals. The company is dedicated to improving patient care by revolutionizing diagnostic testing through its proprietary barcoded magnetic bead technology. With a team of highly skilled scientists and engineers, Applied BioCode Corp has gained recognition for its advanced diagnostic platforms that offer high throughput, multiplex capability, and cost-effectiveness. The company continues to expand its product portfolio and collaborate with industry partners to address the evolving needs of the healthcare industry.

Applied BioCode Corp has achieved several significant milestones in its journey. The company has made strides in the development and commercialization of its proprietary Barcoded Magnetic Bead (BMB) technology. This innovative technology offers multiplex testing capabilities, enabling simultaneous analysis of multiple targets, including genes, proteins, and pathogens. Applied BioCode Corp has successfully launched its FDA-cleared BioCode MDx 3000 system, which allows complex diagnostic testing with high precision and speed. Additionally, the company has secured strategic partnerships and collaborations with major healthcare institutions, facilitating the adoption of its BMB technology. Through these achievements, Applied BioCode Corp has established itself as a leader in the field of molecular diagnostics.

Applied BioCode Corp is primarily present in the United States, particularly in the state of California.

Applied BioCode Corp is a prominent biotechnology company that values innovation, integrity, and excellence. With a strong corporate philosophy, Applied BioCode Corp focuses on developing cutting-edge technologies and solutions to revolutionize diagnostics and improve patient care. By merging the fields of molecular diagnostics and multiplex biomarker detection, the company aims to address unmet clinical needs. Applied BioCode Corp is committed to providing accurate and efficient diagnostic products that empower healthcare professionals and ultimately enhance patient outcomes. With its forward-thinking approach and commitment to quality, Applied BioCode Corp strives to contribute to the advancement of healthcare and improve global health outcomes.

9 analysts currently rate the Applied BioCode stock: 0 recommend buying, 3 holding and 6 selling.

Applied BioCode Cenovna tarča analitikov 2026

Converted at the current exchange rate, the Applied BioCode share trades at 0,83 EUR (31,10 TWD).

Applied BioCode Corp is a leading company in the field of molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable complex biochemical analysis with high accuracy, reliability, and throughput capacity. The business model of Applied BioCode Corp is based on the development and commercialization of diagnostic systems and products for food and water analysis, clinical diagnostics, and research. The company offers innovative solutions to meet the needs of customers in various industries. Applied BioCode Corp's main division is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal tract infections by simultaneously analyzing multiple samples for different bacteria, viruses, and parasites. Another product of the company is the BioCode Respiratory Pathogen Panel (RPP) system, which enables rapid and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP provides an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also produces labeling products such as BioCode screening platforms to enable customers to accurately and timely identify pathogens. The company also offers a wide range of sampling methods and accessories to meet the requirements of diverse customers and applications. Applied BioCode Corp's products are distributed worldwide and are used in various industries, such as food and water analysis, clinical diagnostics, and research. The company focuses on offering innovative solutions to its customers to help meet their needs in terms of analysis, diagnosis, and results. Applied BioCode Corp also operates partnerships and collaborations with other companies to introduce and further develop its systems and products in new areas. The company is constantly striving to improve the quality and accuracy of its products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a company that specializes in the development and commercialization of innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. It offers its customers accurate and reliable solutions to meet their requirements and enhance their efficiency. With an advanced product portfolio, global trade partners, and a dedicated team of professionals, Applied BioCode Corp is undoubtedly one of the leading companies in the field of molecular diagnostics. Applied BioCode Corp is a leading company specializing in molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable highly accurate, reliable, and high-throughput complex biochemical analyses. Their business model focuses on developing and marketing diagnostic systems and products for food and water analysis, clinical diagnostics, and research. They offer innovative solutions to meet the needs of customers in various industries. One of their main divisions is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal infections by simultaneously analyzing multiple samples for various bacteria, viruses, and parasites. Another product is the BioCode Respiratory Pathogen Panel (RPP) system, providing fast and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP offers an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also manufactures labeling products such as BioCode screening platforms, allowing for precise and timely identification of pathogens. They also offer a wide range of sampling methods and accessories to fulfill the requirements of different customers and applications. Their products are distributed worldwide and utilized in various industries including food and water analysis, clinical diagnostics, and research. The company focuses on providing customers with innovative solutions to fulfill their analytical, diagnostic, and result-related needs. They also engage in partnerships and collaborations with other companies to introduce and advance their systems and products in new areas. Applied BioCode Corp is committed to continuously improving the quality and accuracy of their products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a specialized company that develops and markets innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. Their accurate and reliable solutions help customers meet their requirements and increase efficiency. With their advanced product portfolio, global trade partnerships, and dedicated professional team, Applied BioCode Corp is a leading company in the field of molecular diagnostics.

Prihodkov za Applied BioCode trenutno ni mogoče izračunati.

Dobička za Applied BioCode trenutno ni mogoče izračunati.

Razmerja cena-dobiček za Applied BioCode trenutno ni mogoče izračunati.

Razmerja cena-prihodki za Applied BioCode trenutno ni mogoče izračunati.

Eulerpool ocena kvalitete za Applied BioCode je 4/10.

ISIN Applied BioCode je KYG0488D1051. ISIN (International Securities Identification Number) je svetovni edinstven identifikator za vrednostne papirje.

Ticker Applied BioCode je 6598.TW. Ticker simbol se uporablja za trgovanje z delnicami Applied BioCode na borzi.

Applied BioCode je izplačevala dividende vsako leto v zadnjih 0 letih.

Applied BioCode je uvrščena v sektor 'Zdravstvo'.

Dividende Applied BioCode so izplačane v TWD.

Vse ključne kazalnike in poglobljeno analizo Applied BioCode v detaljnem pregledu

Naša analiza delnic Applied BioCode vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (P/E), razmerje cena/prihodki (P/S), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Applied BioCode. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize:

Applied BioCode Delnica
Applied BioCode Prihodki→
Applied BioCode Delnica
Applied BioCode Čisti dobiček→
Applied BioCode Delnica
Applied BioCode KGV→
Applied BioCode Delnica
Applied BioCode KUV→
Applied BioCode Delnica
Applied BioCode EBIT→
Applied BioCode Delnica
Applied BioCode Dividenda→
Applied BioCode Delnica
Applied BioCode Kupnje notranjih oseb→
Applied BioCode Delnica
Applied BioCode Delnice→
Applied BioCode Delnica
Applied BioCode Tržna kapitalizacija→
Applied BioCode Delnica
Applied BioCode Dolg→
Applied BioCode Delnica
Applied BioCode Obveznosti→
Applied BioCode Delnica
Applied BioCode Lastniški kapital→
Applied BioCode Delnica
Applied BioCode AAQS→
Applied BioCode Delnica
Applied BioCode Zaposleni→
Applied BioCode Delnica
Applied BioCode ROE→
Applied BioCode Delnica
Applied BioCode ROA→
Applied BioCode Delnica
Applied BioCode ROCE→
Applied BioCode Delnica
Applied BioCode News→
Applied BioCode Delnica
Applied BioCode Cenovna tarča analitikov→

Zdravstvo Delnice

Applied BiosciencesAppili TherapeuticsAprea TherapeuticsApollomicsAprilBio CoApollo Hospitals EnterpriseAprogen BiologicsAPOLLO BioWellnessAPT MedicalApogee TherapeuticsAptaBio TherapeuticsApimeds Pharmaceuticals USVse delnice A–Z →